

CONTACTS:

Brent Larson,
Vice President / CFO
614 822 2330

Tim Ryan,
The Shoreham Group
212 242 7777

NEOPROBE TO PRESENT AT ROTH CAPITAL PARTNERS 22ND ANNUAL OC GROWTH STOCK CONFERENCE

DUBLIN, OHIO – March 9, 2010 --Neoprobe Corporation (OTCBB: NEOP) , a diversified developer of innovative oncology surgical and diagnostic products, today announced that its President and CEO, David Bupp, will present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference on Monday, March 15, 2010 at 4:00PM PST. The conference is taking place at the Ritz-Carlton in Laguna Niguel, CA. Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical and regulatory status of Neoprobe's two drug development products, Lymphoseek[®] and RIGScan[™] CR.

A live audio webcast of this presentation and copy of the presentation slides will be available at:

<http://www.wsw.com/webcast/roth23/neop.ob/>

A replay of the presentation will also be available at the same site following the live webcast.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe[®] GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek[®] and RIGScan[™] CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com